Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States.

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

Fitusiran is being developed for haemophilia A and B in partnership with RNA interference (RNAi) specialist Alnylam – but has already been affected by safety issues.

5) Sanofi and Alnylam's fitusiran, a once-monthly small interfering RNA (siRNA) therapy for haemophilia A and B that works by inhibiting SerpinPC1 mRNA, reducing antithrombin levels, promoting ...

Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy ...

The gene therapy BBM-H901 (dalnacogene ponparvovec) has been approved in China for adults with moderate to severe hemophilia ...

Are Interval Breast Cancer Diagnoses Increasing? The incidence of interval breast cancer has increased over a 30-year period while the proportion has remained steady. Researchers analyzed factors ...

The bleeding disorders community reminds me of that massive oak tree.

Amvuttra (vutrisiran) Transthyretin-directed small interfering RNA therapeutic Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce ...